Phio Pharmaceuticals Appoints R. Todd Plott, M.D. to Board

What Happened

• Phio Pharmaceuticals (PHIO) announced it increased its Board to six members and appointed R. Todd Plott, M.D. to the Board effective July 20, 2026. Dr. Plott will serve until the Company’s 2026 annual meeting of stockholders and has been named to the Board’s Governance Committee. The Company issued a press release about the appointment on July 21, 2026.

Key Details

• Board size increased to six members; appointment effective July 20, 2026.
• Dr. R. Todd Plott, M.D. is a board-certified dermatologist, researcher, inventor and former FDA advisory committee member with >30 years of experience.
• Dr. Plott will enter the Company’s standard indemnification agreement (covering defense costs, judgments, fines, settlements as applicable).
• He will receive the Company’s standard non-employee director compensation and equity awards (see Director Compensation in Phio’s 10‑K filed March 5, 2026). No related-party transactions or special arrangements were disclosed.

Why It Matters

• For investors, this is a governance update: a new independent director with significant dermatology and regulatory experience has joined the Board and its Governance Committee. The appointment may strengthen the Board’s expertise in areas relevant to Phio’s clinical and regulatory strategy. The indemnification and standard compensation terms are routine disclosures for non-employee directors.